316 related articles for article (PubMed ID: 32393215)
1. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
4. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Res; 2019 Oct; 20(1):241. PubMed ID: 31666076
[TBL] [Abstract][Full Text] [Related]
5. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
[TBL] [Abstract][Full Text] [Related]
6. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Med; 2019 Jul; 153():38-43. PubMed ID: 31150963
[TBL] [Abstract][Full Text] [Related]
7. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.
Donohue JF; Ferguson GT; Ohar JA; Lombardi DA; Schneider RF; Johnson K
Respir Med; 2023 Mar; 208():107123. PubMed ID: 36681255
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
9. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Hvisdas C
Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
Ohar J; Tosiello R; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
[TBL] [Abstract][Full Text] [Related]
11. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
12. Revefenacin for the treatment of chronic obstructive pulmonary disease.
Li F; Yang J
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):293-298. PubMed ID: 30803279
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
Vogelmeier CF; Jones PW; Kerwin EM; Boucot IH; Maltais F; Tombs L; Compton C; Lipson DA; Bjermer LH
Respir Res; 2021 Oct; 22(1):279. PubMed ID: 34711232
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
[TBL] [Abstract][Full Text] [Related]
17. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials.
Donohue JF; Feldman G; Sethi S; Barnes CN; Pendyala S; Bourdet D; Crater G
Pulm Pharmacol Ther; 2019 Aug; 57():101808. PubMed ID: 31152911
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
